Here’s the thing. Stryker’s fundamental demand story never broke. The company got hit by a cybersecurity incident the company identified on March 11, and it caused broad disruption to its Microsoft environment. What is verifiable is that the incident drove operational disruption and contributed to idle production time and higher manufacturing and supply chain costs in Q1. What is not verifiable from Stryker’s filings is that the incident was “Iran-linked,” that it cost “roughly three weeks of production,” or that it drove “approximately $375 million” of deferred or lost sales. What is verifiable is the end result: what should have been a clean, mid-teens organic growth quarter instead came in at 2.4% organic net sales growth and sent the stock to lows nobody expected.
The stock closed at $294.73 on May 1 after Q1 earnings dropped. It had been as high as $404.87 earlier in the year. That gap, roughly 27%, is the setup that traders are now watching heading into Q2 results on July 30.
What the Numbers Actually Show
Q1 revenue came in at $6.02 billion. Organic net sales increased 2.4%. Adjusted EPS was $2.60. On their own, those numbers look like a broken business. They aren’t. The cyber incident explanation isn’t spin. SEC filings confirmed a real disruption and the company disclosed the incident in a March 11, 2026 Form 8-K. In its April 30, 2026 Q1 release, the CEO said it directly: “We remain committed to meeting our full year guidance for organic sales growth and adjusted earnings per share as our underlying business momentum remains strong.”
What management said next mattered more. Full-year guidance held at organic net sales growth of 8.0% to 9.5% and adjusted EPS of $14.90 to $15.10. CFO Preston Wells is the CFO. Separately, multiple analysts took the recovery path at face value. BMO Capital initiated coverage with an Outperform and a $369 target. Argus raised its target to $370. Piper Sandler reiterated an Overweight rating with a $420 target.
For Q2, consensus is looking for $3.46 adjusted EPS and $6.56 billion in revenue. That’s the first clean data point post-disruption. If Stryker hits those numbers, and especially if it beats them, the recovery thesis gets meaningful confirmation.
The Mako Story Is Not Slowing
Slightly tangential but relevant: one of the structural debates around Stryker this year has been whether robotic competition would start eating into the Mako platform’s dominance. The data so far says no. The Mako installed base has surpassed 3,000 systems worldwide. Stryker also launched Mako RPS commercially in July, expanding the platform into a new segment of the market.
That product cycle matters because it creates a recurring revenue flywheel. Each new system installation generates consumables, service contracts, and procedure volume for years. The capital backlog didn’t go away when the cyber incident hit manufacturing. It was just delayed.
The Macro Layer
Healthcare sector performance has been mixed in 2026. Stryker, with roughly a $125B–$129B market cap, sits in an interesting position: it’s a growth medtech name trading at a valuation that has been pressured by an event that doesn’t reflect underlying demand.
One data point worth noting: the Mako Shoulder launch is being closely watched by analysts as the next growth vector after knees and hips. If early uptake tracks Stryker’s historical pattern with new robotic indications, that’s a multi-year growth driver that is not currently priced in at current levels.
Technical Framework
SYK has been grinding back from the May lows. The stock recovered from the $294 area toward the $330 range, but the chart is still well below its 200-day moving average, which sits north of $360. Volume patterns suggest institutional accumulation at lower levels rather than aggressive distribution. The key technical question heading into July 30 is simple: does a strong Q2 report push SYK back above the 200-day and toward the $360 to $370 resistance cluster? Or does another disappointment retest the $290 to $295 support zone?
VWAP from the March cyber incident low has tracked the stock’s recovery angle fairly tightly. A break above that level on earnings volume would be a meaningful momentum signal.
Three Scenarios for July 30
Bull Case
Stryker beats Q2 consensus on both revenue and EPS, demonstrating that deferred Q1 sales were recovered as promised. Management raises or tightens full-year guidance toward the high end. Mako Shoulder launch color is positive. The stock reclaims $360 to $370 on the catalyst and institutional buyers who reduced exposure in Q1 begin rebuilding. Price target range of $369 to $420 from covering analysts becomes the immediate debate.
Base Case
Q2 comes in line with consensus, roughly $6.56 billion in revenue and $3.46 EPS. Management reaffirms full-year guidance without meaningful revision. The stock moves higher but runs into resistance around the $350 to $360 area as investors wait for H2 confirmation that the revenue recovery is complete. Slow grind higher through year-end.
Bear Case
Q2 misses consensus. Recovery from the cyber incident proves slower than management guided. Mako adoption numbers disappoint. Full-year guidance is trimmed. SYK retests the $295 to $300 support zone and the credibility of the recovery story comes into question. This scenario requires either a broader hospital capital spending slowdown or evidence that Stryker’s competitive position in robotics is eroding faster than expected.
Active Trader Framework
The critical number on July 30 is the organic revenue growth rate. If it’s 9% or better, the Q1 cyber incident is confirmed as a one-time disruption. If it’s 6% or below, something structural may be happening that management hasn’t fully acknowledged. Watch the Mako installed-base figure and the commentary on procedure volume trends in orthopaedics. Those are the leading indicators that precede revenue by one to two quarters.
Volatility into earnings has been elevated. Position sizing relative to that volatility is the primary risk management consideration. The stock has a history of moving 3% to 6% on earnings days. The implied earnings move in the options market should be calibrated against that historical range before entering.
Stryker’s story this year has been dominated by a headline that didn’t reflect the business. July 30 is when the business gets to respond.
For informational and educational purposes only. Not investment advice. Trading involves risk, including loss of principal.
